Vanguard Group
OLMA icon

Vanguard Group’s Olema Pharmaceuticals OLMA Stock Holding History

Vanguard Group’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$89M Buy
3,561,355
+364,035
+11% +$6.48M ﹤0.01% 1918
2025
Q3 		$31.3M Sell
3,197,320
-69,679
-2% -$418K ﹤0.01% 2400
2025
Q2 		$13.9M Buy
3,266,999
+395,386
+14% +$1.76M ﹤0.01% 2737
2025
Q1 		$10.8M Buy
2,871,613
+186,604
+7% +$939K ﹤0.01% 2806
2024
Q4 		$15.7M Buy
2,685,009
+152,117
+6% +$1.52M ﹤0.01% 2708
2024
Q3 		$30.2M Sell
2,532,892
-209,772
-8% -$2.68M ﹤0.01% 2398
2024
Q2 		$29.7M Buy
2,742,664
+334,976
+14% +$3.63M ﹤0.01% 2368
2024
Q1 		$27.3M Sell
2,407,688
-298,207
-11% -$3.85M ﹤0.01% 2444
2023
Q4 		$38M Buy
2,705,895
+995,588
+58% +$13.4M ﹤0.01% 2302
2023
Q3 		$21.1M Buy
1,710,307
+36,785
+2% +$375K ﹤0.01% 2529
2023
Q2 		$15.1M Buy
1,673,522
+165,755
+11% +$1M ﹤0.01% 2715
2023
Q1 		$5.23M Buy
1,507,767
+32,417
+2% +$132K ﹤0.01% 3289
2022
Q4 		$3.61M Buy
1,475,350
+721
+0% +$2.1K ﹤0.01% 3445
2022
Q3 		$4.07M Buy
1,474,629
+61,160
+4% +$259K ﹤0.01% 3424
2022
Q2 		$5.75M Buy
1,413,469
+26,274
+2% +$83.3K ﹤0.01% 3299
2022
Q1 		$5.91M Sell
1,387,195
-761,858
-35% -$4.2M ﹤0.01% 3451
2021
Q4 		$20.1M Sell
2,149,053
-592,978
-22% -$12.3M ﹤0.01% 2838
2021
Q3 		$75.6M Buy
2,742,031
+279,776
+11% +$7.55M ﹤0.01% 2145
2021
Q2 		$68.9M Buy
2,462,255
+1,536,117
+166% +$43.7M ﹤0.01% 2198
2021
Q1 		$30.7M Buy
926,138
+122,441
+15% +$5.25M ﹤0.01% 2580
2020
Q4 		$38.6M Buy
+803,697
New +$37.7M ﹤0.01% 2330

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group's OLMA Position: Q4 2025 in Review

Vanguard Group increased its Olema Pharmaceuticals (OLMA) stake by 11% in Q4 2025, buying an estimated $6.48M and bringing the position to 3,561,355 shares worth $89M. The position accounts for ﹤0.01% of the portfolio, ranked #1918.

Vanguard Group first reported a position in OLMA in Q4 2020 and has held it in 21 quarters since. 200 funds tracked by Wall St. Rank hold OLMA as of Q4 2025.

  • Vanguard Group held 3,561,355 shares of Olema Pharmaceuticals worth $89M as of Q4 2025.
  • Vanguard Group bought 364,035 Olema Pharmaceuticals shares in Q4 2025, an estimated $6.48M.
  • Olema Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1918 holding.
  • Vanguard Group first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • 200 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.